References
- 1. Jakupec MA, Galanski M, Keppler BK. Tumour-inhibiting platinum complexes-state of the art and future perspectives. Rev Physiol Biochem Pharmacol. 2003; 146: 1-53.
- 2. Wong E, Giandomenico CM. Current Status of Platinum- Based Antitumor Drugs. Chem. Rev. 1999; 99(9): 2451-66.
- 3. Desoize B, Madoulet C. Particular aspects of platinum compound used at present in cancer treatment. Crit Rev Oncol Hematol. 2002; 42(3): 317-25.
- 4. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007; 33(1): 9-23.
- 5. Bugarcic ZD, Bogojeski J, Petrovic B, Hochreuther S, Eldik R. Mechanisitic studies on the reactions of platinum(II) complexes with nitrogen- and sulfur- donor biomolecules. Dalton Trans. 2012; 41(40): 12329-45.
- 6. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014; 740: 364-78.
- 7. Schimmel KJM, Richel DJ, Van Den Brink RBA, Guchelaar HJ. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev. 2004; 30(2): 181-91.
- 8. Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin Nephrotoxicity: A Review. The Am J Med Sci. 2007; 334(2): 115-24.
- 9. Miller PR, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of Cisplatin Nephrotoxicty. Toxins. 2010; 2(11): 2490-518.
- 10. Mc Whinney SR, Goldberg RM, Mc Leod HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther. 2009; 8(1): 10-6.
- 11. Ding D, Allman BL, Salvi R. Review: Ototoxic Characteristics of Platinum Antitumor Drugs. Anat Rec (Hoboken). 2012; 295(11): 1851-67.
- 12. Chirino YI, Pedraza-Chaverri J. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol. 2009; 61(3): 223-42.
- 13. Döring HJ, Dehnert H. The isolated perfused warmblooded heart according to Langendorff. In: Döring C (Ed.): Methods in Experimental Physiology and Pharmacology. Biological Measurement Techniques. Berlin, Germany: Biomesstechnik-Verlag, 1988: pp. 1-129
- 14. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979; 95(2): 351-8.
- 15. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite and [15N] nitrate in biological fluids. Anal Biochem. 1982; 126(1): 131-8.
- 16. Auclair C, Voisin E. Nitroblue tetrazolium reduction. In: Greenvvald Ra Hadnbook of methods for oxygen radical research. CRC Press Une, Boca Raton. 1985: 123-32.
- 17. Pick E, Keisari Y. A simple colorimetric method for the measurement of hydrogen peroxide produced by cells in culture. J immunol Methods. 1980: 38(1-2); 161-70.
- 18. Jordan P, Carmo-Fonesca M. Molecular mechanisms invoved in cisplatin cytotoxicity. Cell Mol. Life Sci. 2000; 57(8-9): 1229-35.
- 19. Arola OJ, Saraste A, Pulkki K et al. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res. 2000; 60(7): 1789-92.
- 20. Icli F, Karaouguz H, Dincol D et al. Sever vascular toxicity associated with cisplatin-based chemotherapy. Cancer. 1993; 72(2): 587-93.
- 21. Dieckmann KP, Struss WJ, Budde U. Evidence for acute vascular toxicity of cisplatin-based chemotherapy in patients with germ cell tumour. Anticancer res. 2011; 31(12): 4501-6.
- 22. Galanski M, Keppler BK. Synthesis and characterization of new ethylendiamine platinum(IV) complexes containg lipophilic carboxylate ligands. Metal Based Drugs. 1995; 2: 57-63.
- 23. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents. Drug Saf. 2000; 22(4): 263-302.
- 24. Ferroni P, Della-Monte D, Palmirotta R et al. Platinumbased compounds and risk for cardiovascular toxicity in the elderly: role of the antioxidants in chemoprevention. Rejuventation Res. 2011; 14(3): 293-308.
- 25. Al-Majed AA, Sayed-Ahmed AA, Al-Yahya AA, Aleisa AM, Al-Rejaie SS, Al-Shabanah OA. Propionyl-L-carnitine prevents the progression of cisplatin-induces cardiomyopathy in a carnitine-depleted rat model. Pharmacol Res. 2010; 53(3): 278-86.
- 26. Ma H, Jones KR, Guo R, Xu P, Shan Y, Ran J. Cisplatin compromises myocardial contractile function and mitochondrial ultrastructure: role of endoplasmic reticulum stress. Clin. Exp. Pharmacol. Physiol. 2010; 37(4): 460-5.
- 27. Yousef MI, Saad AA, El-Shennawy LK. Protective effect of grape seed proanthocyanidin extract against oxidative stress induced by cisplatin in rats. Food Chem Toxicol. 2009; 47(6): 1176-83.
- 28. Damian G. Deavall, Elizabeth A.Martin, Judith M. Horner, and Ruth Roberts. Drug-Induced Oxidative Stress and Toxicity. J Toxicol. 2012; 1-13.
- 29. Yuce A, Atessahin A, Ceribasi AO, Aksakal M. Ellagic acid prevents cisplatin-induced oxidative stress in liver and heart tissue of rats. Basic Clin Pharmacol Toxicol. 2007; 101(5): 345-9.
- 30. El-Sawalhi MM, Ahmed LA. Exploring the protective role of apocynin, a specific NADPH oxidase inhibitor, In cisplatin-induced cardiotoxicityin rats. Chem Biol Interact.2014; 207: 58-66.
- 31. Hussein A, Ahmed AAE, Shouman SA, Sharawy S. Ameliorating effect of DL-α-lipoic acid against cisplatin- induced nephrotoxicity and cardiotoxicity in experimental animals. Drug Discov Ther. 2012; 6(3): 147-56.
- 32. Baek SM, Kwon CH, Kim JH, Woo JS, Jung JS, Kim YK. Differential roles of hydrogen peroxide and hydroxyl radical in cisplatin-induced cell death in renal proximal tubular epithelial cells. J Lab Clin Med 2003; 142(3): 178-86.
- 33. Sawicka E, Długosz A, Jedrzejczyk J. Antioxidative Enzyme Activities after Exposure to KP972 and Cisplatin. Adv Clin Exp Med 2011; 591-7.
- 34. Kadikoylu G, Bolaman Z, Demir S, Balkaya M, Akalin N, Enli Y. The effects of desferrioxamine on cisplatin induced lipid peroxidation and the activities of antioxidant enzymes in rat kidneys. Hum Exp Toxicol 2004; 23(1): 29-/34.
- 35. Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Perez JM. Biochemical Mechanisms of Cisplatin Cytotoxicity. Anticanc Anticancer Agents Med Chem. 2007; 7(1): 3-18.
- 36. Martins NM, Santos NA, Curti C, Bianchi ML, Santos AC. Cisplatin induces mitochondrial oxidative stress with resultant energetic metabolism impairment, membrane rigidification and apoptosis in rat liver. J. Appl. Toxicol. 2008; 28(3): 337-44.
- 37. Ko JW, Lee IC, Park SH. Protective effects of pine bark extract against cisplatininduced hepatotoxicity andoxidative stress in rats. Lab Anim Res. 2014; 30(4): 174-80.
- 38. Antunes LMG, Darin JDC, Bianchi MDL. Protective effects of vitamin C against cisplatin-induced nephrotoxicity and lipid peroxidation in adult rats: a dosedependent study. Pharmacol Res. 2000; 41(4): 406-11.
- 39. Ciftci O, Ozdemir I, Vardi N, Gurbuz N. Novel platinum- N-heterocyclic carbine complex is more cardiotoxic than cis-platin in rats. Hum Exp Toxicol. 2010; 30(9): 1342-9